Preliminary results suggest that VRC01 -- an investigational HIV neutralising monoclonal antibody -- administered subcutaneously to neonates is safe and well tolerated.
Daily raltegravir was safe and well tolerated at six weeks of life and met pharmacokinetic targets in HIV-exposed infants, according to data presented at CROI 2017.
Tenofovir alafenamide (TAF) and its metabolite tenofovir (TFV) exposures are slightly higher in children aged 6-12 years compared with adults.
The prevalence of transmitted drug resistance is above the WHO threshold of 5% in this study conducted in rural South Africa.
"We believe this is one of the first immune-based therapies to show a very profound reduction in inflammatory markers in the setting of treated HIV," Priscilla Hsue, M.D. states.
The experimental integrase inhibitor being developed by Gilead Sciences is currently in phase III clinical trials.